相似文献
1
Influence of meso-caval shunt surgery on verapamil kinetics, bioavailability and response.肠系膜上静脉-腔静脉分流术对维拉帕米动力学、生物利用度及反应的影响。
Br J Clin Pharmacol. 1980 Nov;10(5):527-30. doi: 10.1111/j.1365-2125.1980.tb01800.x.
2
[Drugs with first-pass elimination. Verapamil and dihydroergotamine alkaloids].[具有首过消除效应的药物。维拉帕米和二氢麦角胺生物碱]
Internist (Berl). 1982 Nov;23(11):610-5.
3
Superiority of stable isotope techniques in the assessment of the bioavailability of drugs undergoing extensive first pass elimination. Studies of the relative bioavailability of verapamil tablets.稳定同位素技术在评估经历广泛首过消除的药物生物利用度方面的优越性。维拉帕米片相对生物利用度的研究。
Eur J Clin Pharmacol. 1981 Jan;19(2):127-31. doi: 10.1007/BF00568399.
4
Influence of cimetidine on verapamil kinetics and dynamics.
Clin Pharmacol Ther. 1984 Oct;36(4):551-4. doi: 10.1038/clpt.1984.218.
5
[Hemodynamic studies of spleno-caval shunt].[脾腔分流术的血流动力学研究]
Zhonghua Wai Ke Za Zhi. 1983 Apr;21(4):209-10.
6
[Effect of portasystemic anastomoses in childhood on propranolol pharmacokinetics].[儿童门体静脉吻合术对普萘洛尔药代动力学的影响]
Schweiz Med Wochenschr. 1981 Jul 18;111(29):1088-93.
7
Verapamil pharmacokinetics.维拉帕米的药代动力学。
Br J Clin Pharmacol. 1986 May;21(5):554-5. doi: 10.1111/j.1365-2125.1986.tb02846.x.
8
Prognosis after meso-caval interposition shunt. Experience of eighty-six consecutive cases over a period of ten years.
Int Surg. 1987 Oct-Dec;72(4):191-6.
9
Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis.肝硬化患者维拉帕米的药代动力学、生物利用度及心电图反应
Br J Clin Pharmacol. 1981 Jul;12(1):51-60. doi: 10.1111/j.1365-2125.1981.tb01854.x.
10
The bioavailability of a slow-release verapamil formulation.一种缓释维拉帕米制剂的生物利用度。
Br J Clin Pract Suppl. 1985 Jun;42:9-16.
引用本文的文献
1
CYP induction-mediated drug interactions: in vitro assessment and clinical implications.细胞色素P450酶诱导介导的药物相互作用：体外评估及临床意义
Pharm Res. 2006 Jun;23(6):1089-116. doi: 10.1007/s11095-006-0277-7. Epub 2006 May 26.
2
Differentiation of gut and hepatic first-pass effect of drugs: 1. Studies of verapamil in ported dogs.药物肠道和肝脏首过效应的差异：1. 维拉帕米在移植犬中的研究。
Pharm Res. 2001 Dec;18(12):1721-8. doi: 10.1023/a:1013374630274.
3
Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis.肝硬化患者维拉帕米的药代动力学、生物利用度及心电图反应
Br J Clin Pharmacol. 1981 Jul;12(1):51-60. doi: 10.1111/j.1365-2125.1981.tb01854.x.
4
Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil.使用稳定同位素标记的维拉帕米同时测定 D,L-维拉帕米的静脉和口服药代动力学参数。
Eur J Clin Pharmacol. 1981 Jan;19(2):133-7. doi: 10.1007/BF00568400.
5
Application of stable labelled drugs in clinical pharmacokinetic investigations.稳定标记药物在临床药代动力学研究中的应用。
Clin Pharmacokinet. 1982 Nov-Dec;7(6):490-507. doi: 10.2165/00003088-198207060-00002.
6
Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration.静脉注射后（+）-、（-）-和（±）-维拉帕米的药代动力学
Br J Clin Pharmacol. 1984 Apr;17(4):453-8. doi: 10.1111/j.1365-2125.1984.tb02371.x.
7
Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Studies with deuterated verapamil.慢性给药期间高清除率药物首过消除的个体间和个体内差异。氘代维拉帕米的研究。
Eur J Clin Pharmacol. 1984;26(1):47-53. doi: 10.1007/BF00546708.
8
Clinical pharmacokinetics of verapamil.维拉帕米的临床药代动力学
Clin Pharmacokinet. 1984 Jan-Feb;9(1):26-41. doi: 10.2165/00003088-198409010-00002.
9
Calcium antagonists. Pharmacokinetic properties.钙拮抗剂。药代动力学特性。
Drugs. 1983 Feb;25(2):113-24. doi: 10.2165/00003495-198325020-00002.
10
Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.维拉帕米、硝苯地平和地尔硫䓬的临床药代动力学。
Clin Pharmacokinet. 1986 Nov-Dec;11(6):425-49. doi: 10.2165/00003088-198611060-00002.
本文引用的文献
1
The disposition of propranolol. I. Elimination during oral absorption in man.普萘洛尔的处置。I. 人体口服吸收过程中的消除
Pharmacology. 1972;7(3):159-68. doi: 10.1159/000136285.
2
Effect of portacaval shunt on the disposition of drugs with and without first-pass effect.
J Pharmacol Exp Ther. 1975 Dec;195(3):416-23.
3
Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.线性药代动力学方程允许根据已拟合数据的多指数方程的系数和指数直接计算许多所需的药代动力学参数。
J Pharmacokinet Biopharm. 1976 Oct;4(5):443-67. doi: 10.1007/BF01062831.
4
Physiological disposition of verapamil in man.维拉帕米在人体中的生理分布。
Cardiovasc Res. 1976 Sep;10(5):605-12. doi: 10.1093/cvr/10.5.605.
5
6
Drug kinetics and hepatic blood flow.药物动力学与肝血流量
Clin Pharmacokinet. 1979 Nov-Dec;4(6):433-48. doi: 10.2165/00003088-197904060-00003.
Zotero 插件